Immunocore Holdings PLCNASDAQ:IMCR
- LAST PRICE31.2100
- TODAY'S CHANGE (%)0.7100 (2.3279%)
- Bid / Lots31.1600/ 1
- Ask / Lots31.2600/ 2
- Open / Previous Close30.6200 / 30.5000
- Day Range
- 52 Week Range
- Volume116,602
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMCR |
|---|---|---|
| 09:32 ET | 855 | 30.62 |
| 09:45 ET | 212 | 30.651 |
| 09:52 ET | 181 | 31.4212 |
| 09:56 ET | 100 | 30.5901 |
| 09:59 ET | 400 | 30.64 |
| 10:03 ET | 635 | 30.725 |
| 10:08 ET | 200 | 30.91 |
| 10:10 ET | 509 | 30.6151 |
| 10:12 ET | 200 | 30.65 |
| 10:15 ET | 2200 | 30.98 |
| 10:28 ET | 100 | 30.845 |
| 10:42 ET | 200 | 30.73 |
| 10:46 ET | 200 | 30.7 |
| 10:48 ET | 100 | 30.715 |
| 10:50 ET | 1300 | 30.77 |
| 10:51 ET | 100 | 30.79 |
| 10:53 ET | 500 | 30.93 |
| 11:00 ET | 100 | 30.905 |
| 11:02 ET | 325 | 31.03 |
| 11:06 ET | 100 | 31.09 |
| 11:08 ET | 720 | 31.22 |
| 11:11 ET | 100 | 31.08 |
| 11:15 ET | 200 | 31.11 |
| 11:22 ET | 100 | 31.155 |
| 11:24 ET | 300 | 31.15 |
| 11:29 ET | 300 | 31.26 |
| 11:44 ET | 200 | 31.03 |
| 11:58 ET | 100 | 31.155 |
| 12:02 ET | 1700 | 31.245 |
| 12:05 ET | 300 | 31.34 |
| 12:09 ET | 100 | 31.385 |
| 12:12 ET | 100 | 31.375 |
| 12:16 ET | 200 | 31.41 |
| 12:21 ET | 100 | 31.425 |
| 12:23 ET | 345 | 31.4 |
| 12:25 ET | 165 | 31.395 |
| 12:30 ET | 769 | 31.34 |
| 12:32 ET | 100 | 31.27 |
| 12:36 ET | 5602 | 31.145 |
| 12:38 ET | 1025 | 31.14 |
| 12:39 ET | 9700 | 31.065 |
| 12:41 ET | 1700 | 31.065 |
| 12:43 ET | 900 | 31.06 |
| 12:54 ET | 100 | 31.06 |
| 12:56 ET | 300 | 31.21 |
| 01:12 ET | 463 | 31.35 |
| 01:14 ET | 200 | 31.29 |
| 01:24 ET | 300 | 31.345 |
| 01:30 ET | 193 | 31.335 |
| 01:33 ET | 100 | 31.34 |
| 01:35 ET | 100 | 31.325 |
| 01:39 ET | 1338 | 31.22 |
| 01:44 ET | 100 | 31.2 |
| 01:50 ET | 250 | 31.28 |
| 01:53 ET | 100 | 31.16 |
| 02:02 ET | 135 | 31.0785 |
| 02:04 ET | 200 | 31.05 |
| 02:06 ET | 200 | 31.03 |
| 02:08 ET | 500 | 31.08 |
| 02:09 ET | 100 | 31.08 |
| 02:27 ET | 1035 | 31.14 |
| 02:29 ET | 200 | 31.115 |
| 02:31 ET | 100 | 31.125 |
| 02:38 ET | 250 | 31.0538 |
| 02:40 ET | 100 | 31.13 |
| 02:45 ET | 300 | 31.12 |
| 02:47 ET | 200 | 31.09 |
| 02:49 ET | 100 | 31.21 |
| 02:54 ET | 100 | 31.25 |
| 02:56 ET | 100 | 31.17 |
| 03:03 ET | 400 | 31.23 |
| 03:05 ET | 200 | 31.24 |
| 03:07 ET | 700 | 31.24 |
| 03:09 ET | 100 | 31.275 |
| 03:12 ET | 200 | 31.275 |
| 03:14 ET | 100 | 31.21 |
| 03:20 ET | 900 | 31.2 |
| 03:21 ET | 469 | 31.23 |
| 03:23 ET | 100 | 31.26 |
| 03:27 ET | 22281 | 31.165 |
| 03:30 ET | 400 | 31.17 |
| 03:34 ET | 1100 | 31.22 |
| 03:36 ET | 400 | 31.22 |
| 03:41 ET | 100 | 31.21 |
Sep 17, 2024
DJ Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 6:21AM ET on Tuesday Sep 17, 2024 by Dow Jones
6:21AM ET on Tuesday Sep 17, 2024 by Dow JonesDJ Immunocore Holdings Is Maintained at Buy by Needham, from 6:04AM ET on Tuesday Sep 17, 2024 by Dow Jones
6:04AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 14, 2024
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer, from 3:00AM ET on Saturday Sep 14, 2024 by Dow Jones
3:00AM ET on Saturday Sep 14, 2024 by Dow Jones
Sep 12, 2024
Immunocore to present at the 2024 Cantor Global Healthcare Conference, from 4:05PM ET on Thursday Sep 12, 2024 by Dow Jones
4:05PM ET on Thursday Sep 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immunocore Holdings PLC | 1.5B | -29.2x | --- |
Innoviva Inc | 1.2B | 11.8x | -8.76% |
Evolus Inc | 1.1B | -18.2x | --- |
Harrow Inc | 1.8B | -53.3x | --- |
Ligand Pharmaceuticals Inc | 1.9B | 47.2x | -12.71% |
Ocular Therapeutix Inc | 1.4B | -9.0x | --- |
Company Information
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Contact Information
- Headquarters
- 90 Park Drive, Milton Park, AbingdonABINGDON, United Kingdom OX14 4RY
- Phone
- 123-543-8600
- Fax
- ---
Executives
- Independent Chairman of the Board
- John Bell
- Chief Executive Officer, Director
- Bahija Jallal
- Chief Financial Officer, Head of Strategy
- Brian Di Donato
- Chief Human Resource Officer
- Tina St Leger
- Head of Research and Development
- David Berman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $281.5M |
Shares Outstanding | 50.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.07 |
Book Value | $7.42 |
P/E Ratio | -29.2x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -21.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
